Exploring the Importance of Rater Reliability in Drug Development for Alzheimer’s Disease

whitePaper | August 8, 2022

Biopharma R&D professionals generally admit that the current "high-cost, high-risk" development model is unsustainable. Despite technological.

whitePaper | December 16, 2019

The use of FAIR (Findable, Accessible, Interoperable and Reusable) data in drug discovery and development could be transformational. But the pharma industry has been slow to embrace FAIR data — partially because of difficulties in establishing the necessary infrastructure and because of internal culture.

whitePaper | November 21, 2022

Contract manufacturing can enhance the drug development process by creating effective processes, increasing manufacturing efficiencies, and reducing overhead costs.

whitePaper | July 1, 2023

As its title implies, Annex 1 is the European guidance document for good manufacturing practices of medicinal products. As such, it serves as the road map for sterile drug manufacturers to follow in order to arrive at the pathway to the highest level of sterility, assuring that their medicinal drug products deploy operational best practices, are certifiable, and regulatorily safe.

whitePaper | March 15, 2022

Successes in 2021 – New active substance drug launches

whitePaper | March 10, 2023

This pharma messaging guidebook features 20 proven cognitive science techniques that can be used to optimize pharmaceutical claims and messages.